AC-225 is suitable for applications with up to 30,000 users across a modular 2,000 doors, allowing maximum flexibility for securing a growing enterprise. Each AC-225 Access Control Unit (ACU) supports ...
The contract guarantees Eckert & Ziegler a one-time payment of EUR 10 million and additional royalties on Ac-225 sales. For Eckert & Ziegler the licence and collaboration agreement is an important ...
This publication includes existing experiences, lessons learned, challenges and future developments in the production of Ac-225 radiopharmaceuticals for Targeted Alpha Therapy (TAT). This publication ...
Eckert & Ziegler will provide high-quality Ac-225 to support GlyTherix’s clinical research and development activities on innovative alpha radiotherapeutics. In December 2024 Eckert & Ziegler ...
Under the terms of the agreement, ITM will supply the therapeutic medical radioisotope, Ac-225, produced by Actineer™ Inc, ITM's joint venture company with Canadian Nuclear Laboratories, for use in ...
Supply constraints have made Ac-225 a highly-sought asset for targeted radiotherapy initiatives, the analyst, who has a Buy ...
Actinium leads the industry in the application of the alpha-particle emitter actinium-225 (Ac-225), which is the most potent medical-grade radioisotope currently available. Its radiation power is ...
Ariceum Therapeutics is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers.
Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...
With extensive industry leadership experience, Mr. Oliverio is poised to drive Actineer’s global expansion in Actinium-225 (Ac-225) production. Mr. Oliverio joins Actineer with over three ...
The contract guarantees Eckert & Ziegler a one-time payment of EUR 10 million and additional royalties on Ac-225 sales. For Eckert & Ziegler the licence and collaboration agreement is an important ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback